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Summary Human papillomavirus (HPV) is the main risk factorfor invasive cervical cancer. High risk ratios are found in cross-sectional data
on HPV prevalence. The question raised is whether this present evidence is sufficient for making firm recommendations on HPV screening.
A validated cervical cancer screening model was extended by adding HPV infection as a possible precursor of cervical intraepithelial
neoplasia (CIN). Two widely different model quantifications were constructed so that both were compatible with the observed HPV risk ratios.
One model assumed a much longer duration of HPV infection before progressing to CIN and a higher sensitivity of the HPV test than the
other. In one version of the model, the calculated mortality reduction from HPV screening was higher and the (cost-)effectiveness was much
better than for Pap smear screening. In the otherversion, outcomes were the opposite, although the cost-effectiveness of the combined HPV
+ cytology test was close to that of Pap smearscreening. Although small follow-up studies and studies with limited strength of design suggest
that HPV testing may well improve cervical cancer screening, only large longitudinal screening studies on the association between HPV
infection and the development of neoplasias can give outcomes that would enable a firm conclusion to be made on the (cost-)effectiveness of
HPV screening. Prospective studies should address women aged 30-60 years.
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Molecular and epidemiological studies have clearly demonstrated
that HPV is the main risk factor for cervical cancer (IARC
working group, 1995; Zur Hausen, 1994). These epidemiological
studies are case-control studies thatconsistently show a very high-
risk ratio for HPV in women with (precursors of) cervical cancer
compared with controls with negative cytology (Morrison et al,
1991; Munoz et al, 1992; Elut-Neto et al, 1994; De SanJose et al,
1994). The association between CIN and high-risk HPV infection
is stronger in high-grade than in low-grade abnormalities (van den
Brule et al, 1991; Bergeron et al, 1992; Lorincz et al, 1992;
Gaarenstroom, 1994; Kjear et al, 1996) and is well over 90% in
invasive cancers (van den Brule et al, 1991; Bosch et al, 1995). A
few small follow-up studies also corroborate the crucial role of
HPV infections: progression is found almost only in women with
(persistent) high-risk HPV genotypes both in normal (Rozendaal
et al, 1996) and in dysplastic cases (Ho etal, 1995; Remmink et al,
1995). In a small retrospective study on archived false-negative
smears from women with subsequent invasive cervical cancer, the
high-risk HPV types found in the cancers were detected in nearly
100% ofthe preceding smears (Walboomers et al, 1995).
On the other hand, test-positive rates for high-risk HPV types
in women over 30 years of age with normal cytology in North
American and westem European countries vary from 3% to 6%
Received 10 December 1996
Revised 17March 1997
Accepted20 March 1997
Correspondence to: M van Ballegooijen, Department of Public Health,
Faculty of Medicine and Health Sciences, PO Box 1738, 3000 DR
Rotterdam, The Netherlands
(Munoz et al, 1992; Bauer et al, 1993; Cuzick et al, 1995;
Rozendaal et al, 1996). This is much higher than can be explained
by the life-time risk of developing cervical cancer in these coun-
tries. For example, in the Netherlands, the rate for high-risk HPV
types in woman aged 30+ with normal cytology is around 4%,
while the cumulative risk for invasive cervical cancer is around
1%; the risk in women aged 30+ with normal cytology is again
much smaller. Therefore, only a fraction of the infections with
high-risk HPV types will progress to cervical cancer.
The goal ofthis study was to incorporatethe very high observed
HPV-associated risk ratios in a cervical cancer screening model
and to investigate the consequences for HPV screening as
expressed in predicted mortality reduction, negative side-effects
and costs. The outcome ofthe follow-up studies carried out to date
have been incorporated in the model in so far that HPV infections
were assumed to precede HPV-infected neoplasias. They were not
usedforthequantification ofthe model as these studies were small
or interpretation in quantitative epidemiological terms was limited
by their design. The possible impact, however, will be discussed.
The present study focuses on the question of whether recommen-
dations about HPV screening can already be made on the basis of
the available data and, ifnot, what type ofdata will be required to
decrease uncertainty.
MATERIALS AND METHODS
The data
Test-positive rates for high-risk HPV types in women between the
ages of 30 and 60 years were estimated on the basis of empirical
data. Polymerase chain reaction (PCR)-based HPV-positive rates
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Figure 1 The stages and possible transitions in the HPV to CIN to invasive
cervical cancer model. The disease stages that describe non-neoplastic
conditions, and that have been added to the validated CIN to cervical cancer
model, have been shaded
Table 1 Parameter values in model version A and B on the duration of
detectable preclinical stages and the sensitivity of the Pap smear and the
HPV test for these stages
Model version A Model version B
Duration ofstages (years)
HPV[1] that will develop into CIN + HPV 10 1
HPV[2] that will be cleared 1 10
CIN (with or without HPV)[31[41 11.8 11.8
Invasive cancer (with or without HPV) 3.9 3.9
Sensitivity ofHPVtest(%)
HPV[11,[21 100 50
CIN + HPV[3] 100 80
Invasive cancer + HPV15] 100 87.5
GRefers to the numbering of the disease stages in Figure 1.
on cytological material of the cervix from women with negative
cytology are 4% in the Netherlands (Rozendaal et al, 1996), 5.7%
in Portland, Oregon, USA (Bauer et al, 1993) and 4.6% in Spain
(Munoz et al, 1992). PCR-based HPV-positive rates on cytological
material of women with a histologically confirmed diagnosis of
CIN are 71% in Spain and 54% in Colombia (de SanJose et al,
1994), 75% in the USA (Morrison et al, 1991), 72% in the UK
(Cuzick, 1994) and 59% in the Netherlands (Gaarenstroom et al,
1994). HPV rates are higher in high-grade than in low-grade
lesions. Noting that the reported results are of the same order
of magnitude, we summarized them by assuming 4% HPV
positiveness in cytologically negative women and 67% in
women with CIN. On the basis of the worldwide study on histo-
logical material ofBosch et al (1995), we assumed that 95% ofthe
invasive carcinomas were HPV infected, i.e. only 5% of invasive
cervical cancers developed without being preceded by an HPV
infection. In accordance with the results of the Dutch study
(Melkert et al, 1993), HPV-positive rates are assumed to be
constant between 30 and 60 years ofage.
The model
Here, the relationship between HPV and cervical cancer in
a stochastic microsimulation screening model is described.
HPV in the model represents high-risk HPV types (16, 18, 31, 33,
35, 39,45,51-52,54,56,58-59,66,68]. As shown in Figure 1, the
model is based on the hypothesis that the onset of HPV infections
found in invasive cervical cancer and in CIN has preceded these
neoplastic stages. Women who go through an HPV infection either
become clear from the infection or develop HPV-infected CIN,
which either regresses or progresses into HPV-positive invasive
cervical cancer. Women can also develop CIN without an HPV
infection, and this CIN again can regress or progress (only some-
times, see later) into invasive cancer. Allowing for the possibility
that women can develop CIN (with or without HPV) after having
become clear from HPV infection would cause a shift between the
several arms in the model, without affecting the model outcomes
presented in this article; therefore we did not complicate the model
in this manner. This model is an extension of a validated cervical
cancer screening Pap smear model (Koopmanschap et al, 1990a
and b; van Ballegooijen et al, 1992a). According to this model, the
average duration of CIN is 11.8 years and preclinical invasive
cancer is 3.9 years (Table 1). The sensitivity of the Pap smear is
80% in CIN and 87.5% in preclinical invasive carcinoma. These
estimates on duration and sensitivity were derived from the British
Columbia (Canada) screening data (van Oortmarssen and
Habbema, 1991) and were compatible with data on interval
cancers collected by the IARC (IARC, 1986; van Oortmarssen
and Habbema, 1995). The incidence of progressive CIN was
chosen to reproduce cervical cancer incidence and mortality in the
Netherlands between 1965 and 1992. The regression rate was 72%
of disease onset under 35 years, 40% between the ages of 35 and
54 and very low in women aged 54 and over. These estimates
resulted from subtracting progressive CIN from the age-specific
CIN detection rates observed in the Dutch population (PALGA,
1992). When adding HPV infection to the model, the part
describing CIN and invasive cervical cancer was kept unchanged;
the predicted CIN and cervical cancer incidences and prevalences
were not affected. Consequently, previous validations are still
valid. The incidence in the Dutch population accounted foris lower
Table 2 Sensitivity by test (or combination of tests), stage and model version resulting from the values for sensitivity given in Table 1
Stages Any model version Model version A Model version B
Cytology only
Cytology + HPV only Cytology + HPV only
HPV HPV
HPV[']I2] 0 100 100 50 50
CIN + HPV[31 80 100 100 96 80
CIN[4] 80 80 0 80 0
Invasive cancer + HPV[5] 87.5 100 100 98.4 87.5
Invasive cancer(61 87.5 87.5 0 87.5 0
ORefers to the numbering of the disease stages in Figure 1.
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Table 3 Assumptions on the costs by type of procedure, in Dutch guilders
Procedure Costs Costs In the
sensitivity
analyses
Screening Pap smear8 70 Dfl
Repeat Pap smears 100 Dfl
HPV testa 90 Dfl (45/155 Dfl)
Pap smear and HPV test in one screening
sessiona 135 Dfl (90/200 Dfl)
Follow-up session in HPV-positive women
with negative cytology 140 Dfl (280 Dfl)
Diagnostic work-up of the referral when no
neoplasia is found 800 Dfl
Management of CINb (van Ballegooijen
et al, 1995) 3100 Dflc
Curative primary treatment
Microinvasive carcinoma 9500 Dfl
IB Invasive carcinoma 20 200 Dfl
11 + Invasive carcinoma 19 100 Dfl
Care for advanced disease (van Ballegooijen
et al, 1992b) 30 700 Dfl
"Including 25 Dfl in total for costs for carrying out the smear/scrape and the
costs for the women (time and transport, Koopmanschap et al, 1990a). bCIN
with or without HPV infection. cincluding the costs of 15% recurrence of
disease after primary treatment of CIN.
than incidences, forexample, in the UK and the USA [7.8 and 12.9
per 100 000 for the Netherlands and the UK, respectively, in
1978-82 (Jensen et al, 1990) and 9.9 in the USA in 1985 (Parkin et
al, 1993)]. The incidence level however did not influence the
comparison ofscreening strategies.
Two model versions
Because only cross-sectional HPV data were available for the
quantification of the model, there was an identification problem
for the parameters describing HPV infections. Test-positive rates
in women screened for the first time are a result of incidence x
duration x sensitivity. In view of this non-identifiability, we
decided to construct two model quantifications that were
contrasting in HPV-screening outcomes. We varied duration and
sensitivity and adjusted the incidence level to the observed test-
positive rates for HPV. The longer the duration of progressive (to
CIN) HPV infections (stage HPVt't in Figure 1) and the higher the
sensitivity ofthe HPV test, the more effective HPV screening will
be in reducing cervical cancer mortality. In order to minimize the
negative side-effects (i.e. follow-up of HPV-positive women who
will not develop cervical neoplasia), it is favourable to assume a
short duration ofharmless (non-progressive) HPV infection (stage
HPV[2] in Figure 1).
In model quantification A (see Table 1), the extra duration of
the detectable preclinical phase because of HPV detection was
assumed to be 10 years. The assumed sensitivity for HPV was
100% at all stages. Long duration and high sensitivity made model
version A very favourable for HPV screening. In version B of the
model, the detectable preclinical phase was only 1 year longer than
in Pap smear screening, and sensitivity for high-risk HPV types
was considerably lower than in version A. In HPV-infected
neoplasia stages, sensitivity ofthe HPV test was equal to the sensi-
tivity of the Pap smear (80% in HPV-positive CIN and 87.5% in
HPV-positive invasive cancer), and sensitivity was only 50% in
HPV infections withoutneoplasia. Compared with model A, model
B was very unfavourable for HPV screening. The consequences of
Table 4 Model of outcomes: effects and costs of different screening policies in women between 30 and 60 years of age, two model versions. Only the least
frequent HPV screening strategies with the same or higher mortality reduction compared with 3-yearly Pap smear screening are presented. All figures are per
1000 women screened
Any model version Model version A Model version B
Cytology only
3-yearlya Cytology HPV only Cytology HPV only
+ HPV + HPV
10yearlya 10-yearlya 5-yearlya 3-yearlys
Favourable effects
Mortality reduction (%) 79 91 89 80 76b
Life-years gained [n (%)] 65 (88) 68 (93) 66 (90) 66 (89) 62 (85)
Unfavourable effects
Years in follow-up 700 520 290 1760 1790
Costs in Dfl (x 1000)
Screening 650 460 300 800 830
Follow-up of HPV-positive - 60 60 361 470
cases
Follow-up of false-positive 95 35 0.2 65 1.5
cytology'
Diagnosis and treatment
CIN 180 120 80 170 140
Invasive and advanced -190 -220 -210 -195 -185
cancer
Total costs 740 460 230 1200 1250
Ratios (per life-year gained)
Years in follow-up 11 8 4 27 29
Costs 11 400 6800 3500 18300 20 100
aScreening interval. bUsing the HPV test only, according to model B, one would have to screen more frequently than 3-yearly to result in at least the same
mortality reduction as 3-yearly cytology. cAt screening and durng follow-up of HPV-positive cases.
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Table 5 Sensitivity analysis: costs per life-year gained with altemative cost assumptions, as percentage difference with the costs per life-year gained of
3-yearly cytology
Any model version Model version A Model version B
Cytology
only Cytology HPV only Cytology HPV only
3-yearly + HPV + HPV
10-yearly 10-yearly 5-yearly 3-yearly
Baseline cost assumptionsa
11 400 6800 3500 18300 20100
(-40) (-70) (+ 60) (+ 80)
Alternative cost assumptionsb
HPV test, 45 Dfl - 60 - 90 + 25 + 20
HPV test, 155 Dfl - 10 -40 + 110 + 160
HPV follow-up, 280 Dfl - 30 - 60 + 110 + 140
aHPV test, 90 Dfl; HPV follow-up, 140 Dfl. Values in parentheses are percentages. bThese changes in assumptions do not affect the costs per life-yeargained of
11 386 Dfl of 3-yearly cytology. Values are percentages.
the two sets ofassumptions for the sensitivity ofthe test (orcombi-
nation oftests) are given in Table 2.
As aresult ofdifferences in sensitivity ofthe HPV test, the HPV
test-positive rate of scrapes in invasive cervical cancer cases was
(100% sensitivity x 95% invasive cervical cancers with preceding
HPV infections =) 95% in model A and (87.5% x 95% =) 83% in
model B. A high rate is in accordance with some PCR studies on
cytological material ofwomenwith invasive cervical cancer (up to
100%, van den Brule et al, 1991), but a lower rate has been found
in other studies (e.g. 84%, Eluf-Neto, 1994).
Simulated compared with observed HPV test-positive
rates
In both model versions, predicted HPV test-positive rates in the
age group 30-60 years was 4.01% in women with negative
cytology and 67% in women with CIN.
Consequences of true-positive test results
In the simulation, women with only negative tests at screening had
a future screening after the regular screening interval. Women with
positive cytology were followed up and in true-positive cases this
led to the detection ofneoplasia. Women with anegative Pap smear
and apositive HPV test were assumed to be followed up with HPV
tests andPap smears every 6 months. This follow-up stopped either
when the HPV infection was cleared (after which women go back
to screening) orwhenthere was atransition ofthe HPV infection to
HPV-infected CIN (the neoplasia is detected). Detected CIN was
assumed to be managed so that no invasive cancer would develop.
For the management of CIN (diagnosis, treatment and after treat-
ment check-ups), we accounted for 4 years offollow-up. This was
in accordance with current practice in the management of CIN, at
least in the Netherlands (van Ballegooijen et al, 1995).
Consequences offalse-positive test results
Women with borderline (ASCUS) or low-grade abnormalities in
their Pap smears in the Netherlands, and also in many other coun-
tries, are followed up with repeat smears. Some of these women
have negative repeat smears and are referred back for routine
screening. Women with higher-grade abnormalities in their Pap
smears are referred to a gynaecologist. In a proportion of these
women, no neoplasia is found. As the model was adjusted for
histologically confirmed detection rates, these so called 'false-
positive' cytological outcomes have to be accounted for sepa-
rately. We made the following assumptions:
* Five per cent ofthe screening smears generated two repeat
smears in women that did not have neoplasia.
* Five per 10 000 screened women without CIN were referred to
the gynaecologist (PALGA, 1995).
The costs of screening
In order to account for the costs and savings of early detection,
the costs of screening, follow-up, diagnosis and treatment were
considered (Table 3). The true resource costs were assessed forthe
screening Pap smear, the HPV test, colposcopy and radiotherapy.
Costs charged in the Netherlands for the other medical procedures
were used. The costs are presented in Dutch Guilders, for which
the US$ exchange rate during 1995 was, on average, 1.61.
Screening strategies
In both model versions, the effects and costs have been calculated
for several screening strategies for women between the ages of30
and 60 years. We made predictive calculations for 3-yearly
cytology and for six alternative strategies. Within these alternative
strategies, we considered two screening test (or combination of
tests) and three screening schedules.
The screening tests were: cytology plus HPV test and HPV- test
only. In the three screening schedules, women were screened
between 30 and 60 years of age: every 3 years (11 screenings per
woman), every 5 years (seven screenings per woman) and every
10 years (four screenings per woman).
The cost-effectiveness calculations
Calculations were made for a cohort of women who attended all
screenings. Effects, costs and savings of the screenings were
accounted for from birth to death. Outcomes were presented per
1000 women and have not been discounted.
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RESULTS
Mortality reduction, years in follow-up and cost-
effectiveness
The model predictions ofthe main effects and costs ofthe different
combinations of frequency and types of screening tests are
summarized in Table 4. For each ofthe two model versions and for
each ofthe two alternative screening tests (cytology plus HPV test
and HPV test alone), only the policy with the lowest screening
frequency that had the same or higher mortality reduction
compared with 3-yearly Pap smear screening is presented.
According to the model version A, which was favourable for
HPV-screening, the combined test (cytology plus HPV test), even
if performed only once every 10 years, reduced mortality more
(91% vs 79%) than 3-yearly Pap smears. Costs were 37% lower,
mainly because of the less frequent screening, and costs per life-
year gained decreased by 41%. The number of years in follow-up
was 26% lower, and the years in follow-up per life-year gained
decreased by 27%. For 10-yearly screening with the HPV test
only, mortality reduction was also higher than for 3-yearly
cytology and only a little lower (89% vs 91%) than for the
combined test. The costs for HPV only were very low, only 31% of
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Figure 2 Simulated results of a hypothetically observational study using
model A and B: age-specific histologically confirmed CIN detection rates at
Pap smear screening in women who 5 years previously had had a negative
Pap smear, by HPV status 5 years previously and age group at present
screening. *, 5 years previously: cytology -/HPV+; O, 5 years previously:
cytology -/HPV-
the costs of 3-yearly Pap smear screening. Costs per life-year
gained were 69% lower. The number oflife-years spent in follow-
up was less than half (because the repeat smears of the borderline
cytology do not occur in screening for HPV), and this also counts
for the number oflife-years in follow-up per life-yeargained.
The results of model version B, which was unfavourable for
HPV screening, were quite different. Combined screening
performed every 5 years yielded a slightly higher mortality
reduction (80% vs 79%, it was predicted at 77% with 10-yearly
combined screening) than screening with cytology every 3 years
and was 63% more costly, resulting in 60% higher costs per life-
year gained. The number of years in follow-up were 2.5 times
higher, as were the number of years in follow-up per life-year
gained. In the predictions for screening with the HPV test alone,
even a 3-yearly interval did not result in a mortality reduction as
high as with 3-yearly Pap smear screening (the 1 year extra
detectablephase for which sensitivity is 50% is outbalanced by the
5% progressive lesions that are not detectable because they are
HPV negative). Costs per life-year gained and years in follow-up
per life-year gained were 1.8 and 2.6 times as high respectively.
Based on the model version A calculations, a decision might be
made to replace Pap smear screening with HPV screening with a
longer interval. This would lead to a greater mortality reduction at
lower costs in terms of resources and negative side-effects.
However, the model version B calculations suggest that Pap smear
screening should not be replaced by any of the studied HPV
screening strategies; costs and negative side-effects increased,
while prevention ofmortality did not improve.
Sensitivity analyses
We also calculated the costs ofHPV screening assuming that HPV-
positive women with negative cytology would be followed up
every 3 years instead of every 6 months. The resulting total costs
of HPV screening were lower, in particular according to model B
in which cost-effectiveness of the combined test was close to the
cost-effectiveness ofPap smear screening. However, less intensive
follow-up in HPV-positive women would, with current knowl-
edge, not be an acceptable option.
Economies of scale play an important role in the costs of an
HPV test. Our estimate was based on a situation with, on average,
12 000 PCRs per year per laboratory. If the testing was concen-
trated in fewer laboratories, the tests would become cheaper.
Moreover, new developments can cause an increase or decrease in
the costs of routine HPV tests. Therefore, calculations were
repeated under the assumption that the laboratory costs per HPV
test of 65 Dfl were less than one-third, i.e. 20 Dfl, or doubled to
130 Dfl. The total costs per test, including the 25 Dfl for carrying
out the smear/scrape, consequently will be 45 Dfl and 155 Dfl,
respectively, for the HPV test and 90 Dfl and 200 Dfl for the
combined test (Pap smear + HPV test). In our basic calculations, a
follow-up session for HPV-positive women was restricted to an
HPV test and a Pap smear. We repeated the calculations with twice
the costs per follow-up session (280 Dfl instead of 140 Dfl). This
would be approximately the costs incurred when a colposcopy is
added. The results are summarized in Table 5. Options that were
more cost-effective than 3-yearly Pap smear screening remained
more cost-effective and those that were less cost-effective also
remained less cost-effective. The conclusions were, therefore, not
affected by considerable changes in the assumptions about the
costs ofHPV screening.
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DISCUSSION
We produced two model versions that both explained the high
observed risk ratios for high-risk HPV types in women with
cervical neoplasia compared with women with normal cytology. In
addition, they were both compatible with the 'clearance' rates in
repeated HPV tests observed in women with normal cytology. In
model A, this clearance resulted from a short duration of harmless
HPV infection. In model B, the low sensitivity of the HPV test
explained why woman that were HPV positive at a first screening
will often be HPV negative at the next one. The effects of HPV
screening predicted by the two model versions widely differed.
Hence, the high-risk ratios alone were inconclusive for the
outcomes expected from HPV screening.
The first non-cross-sectional evidence for the crucial role of
high-risk HPV infections for the development of cervical cancer
has been found in observational follow-up studies. These studies
show only progression to high-grade neoplasias in the presence of
(persistent) HPV infection. This concerns women with normal
(Rozendaal et al, 1996) and abnormal (Ho et al 1995; Remmink et
al, 1995) cytology. Although these studies are very important for
showing that HPV infection precedes the (progression of)
neoplasia, they are too small (Rozendaal et al, 1996) or have an
inadequate design (Ho et al, 1995; Remmink et al, 1995) for
assessing the duration between HPV infection and the develop-
ment of CIN, and the sensitivity of the HPV test. Nevertheless,
they suggest that the sensitivity for progressive HPV infections is
high and, in that respect, they support our favourable model
version A more than the unfavourable model B. This support
emphasizes how worthwhile it is to carry out the required large
prospective studies on the association between HPV and cervical
neoplasia that hopefully will confirm the 'preliminary' findings.
The presented disease model has a number of simplifications. It
does, for example, not discern low-grade on high-grade pre-
invasive lesions, while HPV-negative CIN cannot become HPV
positive. These simplifications, however, are not important for the
results, and model refinements will be of little help as long as
adequate longitudinal data on HPV detection are not available.
The results ofthe cost-effectiveness calculations concerning the
policies that combine HPV testing and Pap smear screening are
complex and their outcomes could not have been predicted easily.
For the calculations concerning policies using only the HPV test, it
is not surprising that when it takes 10 years for HPV infection to
produce CIN, HPV screening can improve Pap smear screening.
This is clearly not the case when HPV infection precedes CIN
changes only by 1 year. But it is important to realize that these
widely different assumptions are both compatible with the
observed very strong association between HPV infection and
cervical cancer, even if it is accepted that the HPV infection
preceded the neoplastic changes that led to the invasive carci-
nomas. The work of Jenkins et al (1996), who also assessed the
effectiveness of HPV testing as a primary screening tool by using
a stochastic model, illustrates this issue. The authors did not vary
the parameters that are crucial for the outcomes. They used
assumptions on the sensitivity of the HPV test that were very
similar to those in our model version A. In the sensitivity analysis,
the simulated screening situation was further improved (by
assuming that 100% of the cancers develop in the presence of
high-grade HPV), but lower sensitivity was not tested. As far as
duration is concerned, Jenkins' assumptions are intermediate to
ours. Although the authors agreed that selection ofthe progression
parameters (which determine the duration of stages) was not
unique, they did not vary the progression rate of HPV infection
and therefore did not describe the complete range of the possible
(cost-)effectiveness of HPV screening.
To explore the impact of longitudinal data, we simulated an
observational cohort study with the two model versions A and B.
In the simulation, women who entered the study with negative
cytology have a Pap smear 5 years later. Predicted CIN detection
rates in women who at entry were HPV negative and those who
were HPV positive were discemed (Figure 2). As the description
of cervical neoplasia (CIN and invasive cervical cancer) of the
model was the same in both model versions, the detection rate for
CIN at Pap smear screening 5 years after negative cytology was
the same. In version A, however, almost 70% of the women with
histologically confirmed CIN (low and high grade) came from
previously HPV-positive women, whereas in model version B this
was only 20%. This reflects a higher predictive value for future
CIN of a positive HPV test in version A. The fact that longitudinal
outcomes clearly differ in both models means that different longi-
tudinal outcomes can be consistent with present cross-sectional
data and that, once such longitudinal data are available, at least
one (and probably both) of models A and B can be rejected. The
range of combinations of parameter values on duration of HPV
infection and sensitivity of the HPV test that are compatible with
observed data will strongly decrease, and better predictions can be
made of results expected from HPV screening.
Although the cross-sectional data show a strong association
between HPV and cervical neoplasia, the results are insufficient to
arrive at recommendations on screening. The discussion, there-
fore, on the representativeness of the test-positive rates that we
aimed at in our simulation (4% in cytologically negative women,
67% in women with CIN and from 83% to 95% in women with
invasive cervical cancers) is premature. Nonetheless, it is inter-
esting to assess the influence of lower or higher observed HPV
test-positive rates. In women with invasive cancer, the higher the
HPV positiveness, the better this will be for the effectiveness of
HPV screening. Higher test-positive rates in women with normal
cytology and in women with CIN, however, can only mean that
more women who do not develop cervical cancer will be HPV
positive (all women that will develop HPV-positive cervical
cancer are already assumed to be HPV positive before the
development of the cancer). These women will unnecessarily be
detected and followed up, and the negative side-effects and cost of
follow-up will increase. In other words, given that HPV infection
precedes, for example, 95% of the progressive neoplasias, lower
HPV prevalence in the cytologically negative women and in
women with CIN implies less harmless and less costly HPV
screening.
A modelling approach, as presented in this paper, is useful for a
joint analysis of cross-sectional, longitudinal and other relevant
epidemiological data. We will adjust our model as soon as new
evidence becomes available.
Data from large PCR-based cohort studies will accumulate in
the forthcoming years. The fact that many of them are solely
focused on young women should be of major concern. The
Copenhagen study (Kjear et al, 1996) is restricted to women under
30 years of age, and the median age ofthe women in the Portland
study is 34 years (Bauer et al, 1993). Screening for HPV in very
young women would cause many women to be followed-up
(because of the high prevalence in this age group of HPV infec-
tions that will clear) and is therefore not advisable. Moreover, the
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fact that prevalence is so much higher in younger age groups is
also an expression of a different natural history of the HPV infec-
tion (at least a higher clearance rate) in this age group. Follow-up
results from these women are obviously not transferable to the
older age groups. Hence, further cohort studies should aim at
women aged 30-60 years.
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